Source comparison
TB-500 Animal Research Comparison
Myocardial infarction (permanent LAD ligation) Mouse 6 mg/kg IP daily × 7 days starting 24h post-injury Ejection fraction at 28 days (echocardiography) 42% vs 31% (p<0.01); 30% less fibrotic scar area Functional cardiac recovery through progenitor cell reactiv
This comparison does not assign a generated winner or score.
- Myocardial infarction (permanent LAD ligation)
- Mouse
- 6 mg/kg IP daily × 7 days starting 24h post-injury
- Ejection fraction at 28 days (echocardiography)
- 42% vs 31% (p<0.01); 30% less fibrotic scar area
- Functional cardiac recovery through progenitor cell reactivation. Not achievable with anti-inflammatories alone
- Gastrocnemius laceration
- Rat
- 5 mg/kg SC every 48h × 14 days
- Tensile strength at repair site (day 21)
- 35% greater load-to-failure; parallel collagen fiber alignment
- Structural repair quality matters more than speed. TB-500 shifts toward organized tissue instead of scar
- Flexor tendon collagenase injury
- Horse
- 7.5 mg IV weekly × 6 weeks
- Lesion cross-sectional area at 12 weeks (ultrasound)
- 42% reduction; increased type I:type III collagen ratio
- Translates across large-animal models with tendon pathology comparable to human rotator cuff injuries
- Corneal epithelial debridement
- Rabbit
- 0.1% topical solution every 6h until closure
- Time to complete re-epithelialization
- 48h vs 72h; 56% faster cell migration velocity
- Effect persists with dexamethasone co-administration, confirming mechanism is actin-mediated, not inflammation-mediated